Developing new pharmacotherapies for autism

Journal of Internal Medicine

Volumn 274, Issue 4, 2013, Pages 308-320

  Ecker, C ^a   Spooren, W ^b   Murphy, D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Autism; Biomarkers; Drug development; Personalized medicine; Translational research

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ARBACLOFEN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CELL ADHESION MOLECULE; CONTACTIN; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; NEUROLIGIN; NEUROLIGIN 1; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; SCAFFOLD PROTEIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN HYDROXYLASE;

AUTISM; BEHAVIOR; BRAIN LEVEL; BRAIN MATURATION; CELL ASSAY; CLINICAL TRIAL (TOPIC); COPY NUMBER VARIATION; DENDRITIC SPINE; GABAERGIC SYSTEM; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HERITABILITY; HUMAN; MACROCEPHALY; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; POSITRON EMISSION TOMOGRAPHY; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; REVIEW; SYNAPSE; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS; TEMPORAL LOBE; TRANSLATIONAL RESEARCH;

AUTISM; BIOMARKERS; DRUG DEVELOPMENT; PERSONALIZED MEDICINE; TRANSLATIONAL RESEARCH;

ANIMALS; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; DRUG DESIGN; GENOTYPE; HUMANS; PHENOTYPE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84883741375     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12113     Document Type: Review

References (76)

1. Baird G, Simonoff E, Pickles A et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006; 368: 210-5.
2. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 2008; 9: 341-55.
3. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 2007; 17: 103-11.
4. Cochrane database of systematic reviews (Online).
5. Lichtenstein P, Carlström E, Råstam M, Gillberg C, Anckarsäter H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 2010; 167: 1357-63.
6. Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci 2009; 32: 402-12.
7. Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, Vitkup D. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 2011; 70: 898-907.
8. Pinto D, Pagnamenta AT, Klei L et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010; 466: 368-72.
9. Dalva MB, McClelland AC, Kayser MS. Cell adhesion molecules: signalling functions at the synapse. Nat Rev Neurosci 2007; 8: 206-20.
10. Lowery LA, Van Vactor D. The trip of the tip: understanding the growth cone machinery. Nat Rev Mol Cell Biol 2009; 10: 332-43.
11. Song JY, Ichtchenko K, Südhof TC, Brose N. Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses. Proc Natl Acad Sci USA 1999; 96: 1100-5.
12. Chih B, Engelman H, Scheiffele P. Control of excitatory and inhibitory synapse formation by neuroligins. Science 2005; 307: 1324-8.
13. Graf ER, Zhang X, Jin S-X, Linhoff MW, Craig AM. Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell 2004; 119: 1013-26.
14. Jamain S, Quach H, Betancur C et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003; 34: 27-9.
15. Laumonnier F, Bonnet-Brilhault F, Gomot M et al. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 2004; 74: 552-7.
16. Rubenstein JLR, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003; 2: 255-67.
17. Durand CM, Betancur C, Boeckers TM et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007; 39: 25-7.
18. Renner M, Specht CG, Triller A. Molecular dynamics of postsynaptic receptors and scaffold proteins. Curr Opin Neurobiol 2008; 18: 532-40.
19. Hallmayer J, Cleveland S, Torres A et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011; 68: 1095-102.
20. Chamak B. [Autism: overestimation of the genetic origins]. Med Sci (Paris) 2010; 26: 659-62.
21. Flashner BM, Russo ME, Boileau JE, Leong DW, Gallicano GI. Epigenetic factors and autism spectrum disorders. Neuromolecular Med 2013; 15: 339-50.
22. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012; 17: 389-401.
23. Dauncey MJ. Genomic and epigenomic insights into nutrition and brain disorders. Nutrients 2013; 5: 887-914.
24. Szatmari P. Is autism, at least in part, a disorder of fetal programming? Arch Gen Psychiatry 2011; 68: 1091-2.
25. Bale TL, Baram TZ, Brown AS et al. Early life programming and neurodevelopmental disorders. Biol Psychiatry 2010; 68: 314-9.
26. Ebert DH, Greenberg ME. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 2013; 493: 327-37.
27. Schendel DE, Bresnahan M, Carter KW et al. The International Collaboration for Autism Registry Epidemiology (iCARE): multinational Registry-Based Investigations of Autism Risk Factors and Trends. J Autism Dev Disord 2013. [Epub ahead of print]
28. Smith DG, Ehlers MD. Mining and modeling human genetics for autism therapeutics. Curr Opin Neurobiol 2012; 22: 902-10.
29. Peça J, Feliciano C, Ting JT et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011; 472: 437-42.
30. Wang X, McCoy PA, Rodriguiz RM et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet 2011; 20: 3093-108.
31. Baudouin SJ, Gaudias J, Gerharz S et al. Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science 2012; 338: 128-32.
32. Peñagarikano O, Abrahams BS, Herman EI et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 2011; 147: 235-46.
33. Spooren W, Lindemann L, Ghosh A, Santarelli L. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders. Trends Pharmacol Sci 2012; 33: 669-84.
34. Penzes P, Cahill ME, Jones KA, VanLeeuwen J-E, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 2011; 14: 285-93.
35. Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008; 455: 903-11.
36. Courchesne E, Karns CM, Davis HR et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 2001; 57: 245-54.
37. Courchesne E. Abnormal early brain development in autism. Mol Psychiatry 2002; 7(Suppl 2): S21-3.
38. Carper RA, Moses P, Tigue ZD, Courchesne E. Cerebral lobes in autism: early hyperplasia and abnormal age effects. Neuroimage 2002; 16: 1038-51.
39. Gogtay N, Giedd JN, Lusk L et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci USA 2004; 101: 8174-9.
40. Ecker C, Suckling J, Deoni SC et al. Brain anatomy and its relationship to behavior in adults with autism spectrum disorder: a multicenter magnetic resonance imaging study. Arch Gen Psychiatry 2012; 69: 195-209.
41. Herbert MR. Large brains in autism: the challenge of pervasive abnormality. Neuroscientist 2005; 11: 417-40.
42. Ecker C, Rocha-Rego V, Johnston P et al. Investigating the predictive value of whole-brain structural MR scans in autism: a pattern classification approach. Neuroimage 2010; 49: 44-56.
43. Ecker C, Marquand A, Mourão-Miranda J et al. Describing the brain in autism in five dimensions--magnetic resonance imaging-assisted diagnosis of autism spectrum disorder using a multiparameter classification approach. J Neurosci 2010; 30: 10612-23.
44. Coutanche MN, Thompson-Schill SL, Schultz RT. Multi-voxel pattern analysis of fMRI data predicts clinical symptom severity. Neuroimage 2011; 57: 113-23.
45. Lange N, Dubray MB, Lee JE et al. Atypical diffusion tensor hemispheric asymmetry in autism. Autism Res 2010; 3: 350-8.
46. Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev 2012; 36: 2044-55.
47. Owens DF, Kriegstein AR. Is there more to GABA than synaptic inhibition? Nat Rev Neurosci 2002; 3: 715-27.
48. Fatemi SH. The hyperglutamatergic hypothesis of autism. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 911. Author reply 912-3.
49. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2002; 52: 805-10.
50. Trikalinos TA, Karvouni A, Zintzaras E et al. A heterogeneity-based genome search meta-analysis for autism-spectrum disorders. Mol Psychiatry 2006; 11: 29-36.
51. Hogart A, Nagarajan RP, Patzel KA, Yasui DH, Lasalle JM. 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum Mol Genet 2007; 16: 691-703.
52. Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J Autism Dev Disord 2001; 31: 537-43.
53. Oblak A, Gibbs TT, Blatt GJ. Decreased GABAA receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism. Autism Res 2009; 2: 205-19.
54. Harada M, Taki MM, Nose A et al. Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J Autism Dev Disord 2011; 41: 447-54.
55. Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006; 51: 527-39.
56. Mendez MA, Horder J, Myers J et al. The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology 2013; 68: 195-201.
57. Shinohe A, Hashimoto K, Nakamura K et al. Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1472-7.
58. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001; 57: 1618-28.
59. Fatemi SH, Folsom TD, Kneeland RE, Liesch SB. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken) 2011; 294: 1635-45.
60. Page LA, Daly E, Schmitz N et al. In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry 2006; 163: 2189-92.
61. Brown MS, Singel D, Hepburn S, Rojas DC. Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a (1) H-MRS study. Autism Res 2013; 6: 1-10.
62. Gürkan CK, Hagerman RJ. Targeted treatments in autism and fragile X syndrome. Res Autism Spectr Disord 2012; 6: 1311-20.
63. Anderson GM, Horne WC, Chatterjee D, Cohen DJ. The hyperserotonemia of autism. Ann N Y Acad Sci 1990; 600: 331-40. Discussion 341-2.
64. Hranilovic D, Bujas-Petkovic Z, Vragovic R, Vuk T, Hock K, Jernej B. Hyperserotonemia in adults with autistic disorder. J Autism Dev Disord 2007; 37: 1934-40.
65. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961; 58: 315-20.
66. Chugani DC, Muzik O, Behen M et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999; 45: 287-95.
67. Murphy DGM, Daly E, Schmitz N et al. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. Am J Psychiatry 2006; 163: 934-6.
68. Nakamura K, Sekine Y, Ouchi Y et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 2010; 67: 59-68.
69. Nabi R, Serajee FJ, Chugani DC, Zhong H, Huq AHMM. Association of tryptophan 2, 3 dioxygenase gene polymorphism with autism. Am J Med Genet B Neuropsychiatr Genet 2004; 125B: 63-8.
70. Devlin B, Cook EH, Coon H et al. Autism and the serotonin transporter: the long and short of it. Mol Psychiatry 2005; 10: 1110-6.
71. Anderson BM, Schnetz-Boutaud NC, Bartlett J et al. Examination of association of genes in the serotonin system to autism. Neurogenetics 2009; 10: 209-16.
72. Daly E, Deeley Q, Ecker C et al. Serotonin and the neural processing of facial emotions in autism; an fMRI study using acute tryptophan depletion. Arch Gen Psychiatry 2012; 69: 1003-13.
73. Niederhofer H, Staffen W, Mair A. Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Hum Psychopharmacol 2003; 18: 389-93.
74. Wetmore DZ, Garner CC. Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr 2010; 31: 564-81.
75. Murphy D, Spooren W. EU-AIMS: a boost to autism research. Nat Rev Drug Discov 2012; 11: 815-6.
76. Huttner A, Rakic P. Diagnosis in a dish: your skin can help your brain. Nat Med 2011; 17: 1558-9.